Andrew C. Jackson - 17 Jun 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role: Chief Financial Officer
Signature: /s/ Andrew Jackson
Issuer symbol: CLDI
Transactions as of: 17 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 20 Jun 2024, 20:56:01 UTC
Previous filing: 02 Nov 2023
Next filing: 25 Aug 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLDI	Stock Options (right to buy)	Award		+300,000			300,000	17 Jun 2024	Common stock	300,000	$0.1950	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on June 17, 2024 (the "Grant Date"), the Reporting Person was granted 300,000 incentive stock options (the "Options") at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 10/30/2023, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.

Content

Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on June 17, 2024 (the "Grant Date"), the Reporting Person was granted 300,000 incentive stock options (the "Options") at an exercise price of $0.195, which is equal to the closing price of the Issuer's common stock on the Grant Date. 25% of the options will vest upon the one (1) year anniversary of 10/30/2023, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer. The Options were granted in a transaction exempt under Rule 16b-3 to the Reporting Person.